These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 7884393

  • 1. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB, Ben-Shachar D, Riederer P.
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [Abstract] [Full Text] [Related]

  • 2. Modifications of the iron-neuromelanin system in Parkinson's disease.
    Fasano M, Bergamasco B, Lopiano L.
    J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
    [Abstract] [Full Text] [Related]

  • 3. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL.
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [Abstract] [Full Text] [Related]

  • 4. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, Takahashi S, Ehara S, Terayama Y, Sakai A.
    Neuroreport; 2006 Jul 31; 17(11):1215-8. PubMed ID: 16837857
    [Abstract] [Full Text] [Related]

  • 5. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL.
    Prog Neurobiol; 2005 Feb 31; 75(2):109-24. PubMed ID: 15784302
    [Abstract] [Full Text] [Related]

  • 6. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, Zadlo A, Szewczyk G, Zareba M, Sarna T.
    J Neurochem; 2008 Aug 31; 106(4):1866-75. PubMed ID: 18624918
    [Abstract] [Full Text] [Related]

  • 7. Neuromelanin and Parkinson's disease.
    Marsden CD.
    J Neural Transm Suppl; 1983 Aug 31; 19():121-41. PubMed ID: 6321645
    [Abstract] [Full Text] [Related]

  • 8. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E, Santin MD, Valabrègue R, Mangone G, Gaurav R, Pyatigorskaya N, Hutchison M, Yahia-Cherif L, Villain N, Habert MO, Arnulf I, Leu-Semenescu S, Dodet P, Vila M, Corvol JC, Vidailhet M, Lehéricy S.
    Brain; 2021 Nov 29; 144(10):3114-3125. PubMed ID: 33978742
    [Abstract] [Full Text] [Related]

  • 9. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP.
    Mov Disord; 2011 Aug 01; 26(9):1633-8. PubMed ID: 21491489
    [Abstract] [Full Text] [Related]

  • 10. A critical review of the function of neuromelanin and an attempt to provide a unified theory.
    Nicolaus BJ.
    Med Hypotheses; 2005 Aug 01; 65(4):791-6. PubMed ID: 15949901
    [Abstract] [Full Text] [Related]

  • 11. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD, Arai M, Cohen JA, Trojanowski JQ.
    J Comp Neurol; 1993 Mar 15; 329(3):328-36. PubMed ID: 8459049
    [Abstract] [Full Text] [Related]

  • 12. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB, Riederer P.
    J Neural Transm Suppl; 1993 Mar 15; 40():57-67. PubMed ID: 8294901
    [Abstract] [Full Text] [Related]

  • 13. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
    Hirsch E, Graybiel AM, Agid YA.
    Nature; 1988 Jul 28; 334(6180):345-8. PubMed ID: 2899295
    [Abstract] [Full Text] [Related]

  • 14. What process causes nigral cell death in Parkinson's disease?
    Jenner P.
    Neurol Clin; 1992 May 28; 10(2):387-403. PubMed ID: 1584181
    [Abstract] [Full Text] [Related]

  • 15. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, Audrain H, Bender D, Østergaard K, Brooks DJ, Borghammer P.
    Brain; 2016 Jul 28; 139(Pt 7):2039-49. PubMed ID: 27190023
    [Abstract] [Full Text] [Related]

  • 16. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.
    Martín-Bastida A, Lao-Kaim NP, Roussakis AA, Searle GE, Xing Y, Gunn RN, Schwarz ST, Barker RA, Auer DP, Piccini P.
    Brain; 2019 Jul 01; 142(7):2023-2036. PubMed ID: 31056699
    [Abstract] [Full Text] [Related]

  • 17. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E.
    Cell Mol Biol (Noisy-le-grand); 2000 Jun 01; 46(4):709-20. PubMed ID: 10875434
    [Abstract] [Full Text] [Related]

  • 18. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
    Knörle R.
    Neurotox Res; 2018 Feb 01; 33(2):515-522. PubMed ID: 28879408
    [Abstract] [Full Text] [Related]

  • 19. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB, Ben-Shachar D, Riederer P.
    Mov Disord; 1993 Feb 01; 8(1):1-12. PubMed ID: 8419792
    [Abstract] [Full Text] [Related]

  • 20. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits.
    Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, Sabbagh MN, Adler CH.
    Acta Neuropathol; 2007 Oct 01; 114(4):419-24. PubMed ID: 17639428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.